Edgewise Therapeutics (EWTX) said this morning that the FDA deemed the CANYON data alone insufficient for an accelerated approval of sevasemten. “The Agency reiterated that NSAA is a clinically meaningful endpoint for traditional approval,” however, the company added. The shares are down 4%, or 58c, to $13.75 in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics announces results from sevasemten program
- Promising Developments in Edgewise Therapeutics’ Muscular Dystrophy Programs Drive Buy Rating
- Edgewise Therapeutics Reports Strong Q1 2025 Progress
- Edgewise Therapeutics reports Q1 EPS (43c), consensus (42c)
- Controversial doctor Vinay Prasad named CBER director, STAT reports